WO2001072203A3 - Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents - Google Patents

Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents Download PDF

Info

Publication number
WO2001072203A3
WO2001072203A3 PCT/US2001/008446 US0108446W WO0172203A3 WO 2001072203 A3 WO2001072203 A3 WO 2001072203A3 US 0108446 W US0108446 W US 0108446W WO 0172203 A3 WO0172203 A3 WO 0172203A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear targeting
target cell
proliferative disorders
cell nuclei
targeting agents
Prior art date
Application number
PCT/US2001/008446
Other languages
French (fr)
Other versions
WO2001072203A2 (en
Inventor
Robert A Gatenby
Original Assignee
Univ Temple
Robert A Gatenby
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Robert A Gatenby filed Critical Univ Temple
Priority to AU2001255179A priority Critical patent/AU2001255179A1/en
Priority to EP01928305A priority patent/EP1283674A4/en
Publication of WO2001072203A2 publication Critical patent/WO2001072203A2/en
Publication of WO2001072203A3 publication Critical patent/WO2001072203A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of treating proliferative disorders in vivo by the direct administration of tritium to target cell nuclei. Tritium is administered to target cell nuclei by a tritiated nuclear targeting agent, which is directed to the target cell nucleus where it associates with the cell's DNA. The close association of the tritiated nuclear targeting agent with the target cell DNA allows the low-energy beta particle emitted by the tritium to damage to the target cell DNA and kill the cell. Tritiated nuclear targeting agents can also be delivered to the target cells by structures such as liposomes, micelles and microcapsules.
PCT/US2001/008446 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents WO2001072203A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001255179A AU2001255179A1 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
EP01928305A EP1283674A4 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19215300P 2000-03-24 2000-03-24
US60/192,153 2000-03-24
US19267100P 2000-03-28 2000-03-28
US60/192,671 2000-03-28

Publications (2)

Publication Number Publication Date
WO2001072203A2 WO2001072203A2 (en) 2001-10-04
WO2001072203A3 true WO2001072203A3 (en) 2002-10-10

Family

ID=26887786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008446 WO2001072203A2 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Country Status (3)

Country Link
EP (1) EP1283674A4 (en)
AU (1) AU2001255179A1 (en)
WO (1) WO2001072203A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023299A2 (en) * 1996-11-26 1998-06-04 Angiogene Inc. Radiolabeled dna oligonucleotide, method of preparation and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
AU685080B2 (en) * 1993-01-07 1998-01-15 Thomas Jefferson University Antisense inhibition of C-MYC to modulate the proliferation of smooth muscle cells
US5847104A (en) * 1995-05-22 1998-12-08 Hybridon, Inc. Method of tritium labeling oligonucleotide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023299A2 (en) * 1996-11-26 1998-06-04 Angiogene Inc. Radiolabeled dna oligonucleotide, method of preparation and therapeutic uses thereof
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1283674A4 *

Also Published As

Publication number Publication date
EP1283674A4 (en) 2005-04-27
WO2001072203A2 (en) 2001-10-04
EP1283674A2 (en) 2003-02-19
AU2001255179A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
Zhang et al. Polyphenol‐based nanomedicine evokes immune activation for combination cancer treatment
Liu et al. Hypoxia induced by upconversion‐based photodynamic therapy: towards highly effective synergistic bioreductive therapy in tumors
Tolbert et al. Effect of ascorbic acid on neurochemical, behavioral, and physiological systems mediated by catecholamines
Ohno et al. Effective solitary hyperthermia treatment of malignant glioma using stick type CMC-magnetite. In vivo study
Peaston et al. Photodynamic therapy for nasal and aural squamous cell carcinoma in cats
WO2001037721A3 (en) Magnetic nanoparticles for selective therapy
WO2000066066A3 (en) Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
Wang et al. Tumor cell apoptosis induced by nanoparticle conjugate in combination with radiation therapy
WO2006068759A3 (en) Liposomes containing phytochemical agents and methods for making and using same
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
Mohammadi et al. The combination effect of poly (lactic-co-glycolic acid) coated iron oxide nanoparticles as 5-fluorouracil carrier and X-ray on the level of DNA damages in the DU 145 human prostate carcinoma cell line
WO2004034876A3 (en) Magnetically guided particles for radiative therapies
CA2312767A1 (en) Drug delivery system with two-step targeting
Busetti et al. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma
WO2000041725A3 (en) Therapeutic compositions for metabolic bone disorders or bone metastases
EP1204426B1 (en) Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases
WO2001072203A3 (en) Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
Dagrosa et al. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy
CN101090012A (en) Far infrared/strong magnetic fied function material
Liu et al. Effect of DTPP-mediated photodynamic therapy on cell morphology, viability, cell cycle, and cytotoxicity in a murine lung adenocarcinoma cell line
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
JPS6318567B2 (en)
Harrington et al. The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes
US20090258088A1 (en) Use of materials and external stimuli for synovectomy
WO2009090847A9 (en) Alkaline electron radiation device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10221969

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001928305

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928305

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928305

Country of ref document: EP